Welcome to our dedicated page for Mersana Therapeutics news (Ticker: MRSN), a resource for investors and traders seeking the latest updates and insights on Mersana Therapeutics stock.
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancers with high unmet medical need. Its news flow reflects both scientific progress and corporate developments, making the MRSN news page a focused source for investors and observers following oncology drug development and transaction activity.
Company press releases emphasize updates from its ADC pipeline, particularly Emi-Le (emiltatug ledadotin; XMT-1660), a B7-H4-directed Dolasynthen ADC, and XMT-2056, an Immunosynthen ADC targeting a novel HER2 epitope. News items have covered interim Phase 1 clinical data for Emi-Le in triple-negative breast cancer and adenoid cystic carcinoma type 1, including objective response rates and safety observations, as well as plans for dose expansion cohorts and future data readouts. Additional scientific news includes presentations at major oncology congresses such as ASCO and ESMO Breast Cancer.
Mersana’s news releases also detail collaboration milestones with partners including GSK, Janssen Biotech, Inc. (Johnson & Johnson) and Merck KGaA, Darmstadt, Germany. Examples include the achievement of development milestone payments and FDA clearance of an investigational new drug application for a Dolasynthen ADC developed under a collaboration. Corporate and capital markets news has included announcements of quarterly financial results, a 1-for-25 reverse stock split designed to support Nasdaq listing compliance, and notices related to Nasdaq listing standards.
A significant portion of recent news is devoted to the proposed acquisition of Mersana by Day One Biopharmaceuticals, Inc., including the terms of the tender offer, the structure of the contingent value rights and the expected timing of closing. Readers of the MRSN news page can therefore expect a mix of clinical trial updates, collaboration developments, financial disclosures, listing-related actions and transaction announcements. For ongoing context around these events, this page can be revisited as new company communications are released.
Mersana Therapeutics (NASDAQ: MRSN) announced positive initial clinical data from Phase 1 trial of emiltatug ledadotin (Emi-Le), targeting B7-H4 in cancer treatment. The trial enrolled 130 patients with advanced/metastatic cancers, including triple-negative breast cancer (TNBC).
Key findings show Emi-Le was generally well-tolerated with no Grade 4 or 5 treatment-related adverse events. At intermediate doses (38.1-67.4 mg/m2), confirmed objective response rate was 23% across B7-H4 high tumors and TNBC patients previously treated with topo-1 ADCs. The company has initiated expansion in TNBC patients at 67.4 mg/m2 dose.
Notable safety profile includes no dose-limiting treatment-related neutropenia, neuropathy, ocular toxicity, or thrombocytopenia. Common treatment-related adverse events included AST increase (38%), proteinuria (31%), nausea (29%), and fatigue (28%).
Mersana Therapeutics (NASDAQ: MRSN) reported Q3 2024 financial results and provided business updates. The company ended Q3 with $155.2 million in cash, expecting to fund operations into 2026. Q3 revenue was $12.6 million, up from $7.7 million in Q3 2023. Net loss decreased to $11.5 million ($0.09 per share) from $41.7 million ($0.35 per share) year-over-year. The company plans to announce initial clinical data for XMT-1660 by year-end 2024 and is advancing Phase 1 trials for both XMT-1660 and XMT-2056. Mersana achieved milestone payments of $8 million from Johnson & Johnson and $1 million from Merck KGaA collaborations.
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company developing antibody-drug conjugates for cancer treatment, has scheduled its Q3 2024 financial results and business updates conference call for November 13, 2024 at 8:00 a.m. Eastern Time. Investors can access the call via domestic (833-255-2826) or international (412-317-0689) dial-in numbers. A webcast will be available on the company's website, with a replay accessible for approximately 90 days following the presentation.
Mersana Therapeutics (NASDAQ: MRSN) provided a business update and reported Q2 2024 financial results. Key highlights include:
- Advancing Phase 1 trials for XMT-1660 and XMT-2056
- Expecting initial XMT-1660 clinical data and expansion initiation in H2 2024
- $162.7 million cash position as of June 30, 2024
- Capital resources expected to support operations into 2026
- Q2 2024 net loss of $24.3 million ($0.20 per share)
- Collaboration revenue of $2.3 million
- R&D expenses decreased to $17.2 million
- G&A expenses reduced to $10.5 million
- Earned $8 million milestone from Johnson & Johnson collaboration
The company continues to progress its ADC pipeline and collaborations while benefiting from reduced operating expenses.
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer treatment, has announced its upcoming second quarter 2024 financial results and business update conference call. The event is scheduled for Tuesday, August 13, 2024, at 8:00 a.m. Eastern Time. Investors and interested parties can access the call via phone or webcast. The webcast will be available on the company's website for approximately 90 days following the conference call.
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical firm, will present at two upcoming investor conferences. These include the TD Cowen 5th Annual Oncology Innovation Summit on May 29, 2024, at 9:00 a.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, at 8:00 a.m. ET. The company specializes in developing antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs.
Mersana's proprietary ADC platforms, Dolasynthen and Immunosynthen, support a pipeline of product candidates such as XMT-1660 and XMT-2056. Live webcasts and archived replays of these events will be accessible on Mersana's website for 90 days post-event.
Mersana Therapeutics, a clinical-stage biopharmaceutical company, provided a business update and reported financial results for the first quarter of 2024. They are advancing Phase 1 clinical trials for XMT-1660 and XMT-2056, expecting to share initial data and initiate expansion. They continue collaborations and presented data showing platform differentiation. Financially, they have sufficient capital resources into 2026, with collaboration revenue increasing year-over-year.
Mersana Therapeutics, a clinical-stage biopharmaceutical company, granted an inducement award to a new employee on May 1, 2024, under Nasdaq Listing Rule 5635(c)(4). The award consists of a restricted stock unit (RSU) to acquire 35,100 shares of common stock, vesting over four years.
Mersana Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on May 9, 2024, to provide business updates and report financial results for the first quarter of 2024. The company focuses on developing antibody-drug conjugates targeting cancers with high unmet medical needs.
Summary not available.